التاريخ:	--/--/-- --:--:--
مُعرِّف الحدث:	E5CZL3OTR
نوع الإجراء:	ACQUISITION
حالة الإجراء:	COMPLETED
رمز سهم الشركة المستحوِذة:
الرمز المُستهدَف:	ITCI
مُحدَّث:	--/--/-- --:--:--
سعر شراء السهم:	132
عملة سعر السهم الواحد:	USD
مصادر الأخبار:	https://www.businesswire.com/news/home/20250402861736/en/

ملاحظات حول الإجراء

Johnson & Johnson and Intra-Cellular Therapies, Inc announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value of approximately $14.6 billion. The closing of the transaction is expected to occur later this year subject to applicable regulatory approvals, approval by Intra-Cellular Therapies' stockholders and other customary closing conditions for a transaction of this type. Following completion of the transaction, Intra-Cellular Therapies' common stock will no longer be listed for trading on the Nasdaq Global Select Market. The Intra-Cellular special shareholder meeting to vote on the transaction will be held on 03/27. Per PR on 4/1, Johnson & Johnson intends to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025. Following the completion of the transaction, Intra-Cellular Therapies' common stock will cease trading on the NASDAQ Global Select Market.